AnaptysBio, Inc. (ANAB) shares rallied 30.5% in the last trading session to close at $16.15. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Despite premarket gains, shares of AnaptysBio (NASDAQ:ANAB) turned lower on Wednesday following disappointing mid-stage trial data for Johnson & Johnson’s (NYSE:JNJ) anti-inflammatory agent JNJ ...

AnaptysBio, Inc. (NASDAQ:ANAB) is a clinical-stage biotechnology company, focusing on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology.

Within the past quarter, the Zacks Consensus Estimate for ANAB's full-year earnings has moved 15.7% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

AnaptysBio Inc’s (NASDAQ: ANAB) stock seems attractive after the POPLAR data and the 30% selloff, while there are several catalysts over the next 12-18 months, according to Truist Securities ...

AnaptysBio (ANAB) stock gains as H.C. Wainwright upgrades the stock on promising Phase 2b trial data for its rheumatoid arthritis therapy rosnilimab. Read more here.

AnaptysBio (ANAB) stock dips as rival J&J's (JNJ) trial data for its anti-inflammatory agent similar to ANAB's lead asset disappoints in ulcerative colitis. Read more here.

Here are some of the largest recent moves: FIRST LIGHT ASSET MANAGEMENT, LLC added 3,764,720 shares (+433.3%) to their portfolio in Q1 2025, for an estimated $69,986,144 POINT72 ASSET MANAGEMENT ...

It's hard to imagine how the future might look and feel. Anab Jain wants to change that. She designs prototypes of potentially grim futures to raise awareness of our choices in the present.

AnaptysBio Inc. Annual stock financials by MarketWatch. View the latest ANAB financial statements, income statements and financial ratios.